Effects of morphine and naloxone on hippocampal CA3 field potentials following systemic administration in the freely-moving rat

Local hippocampal methamphetamine-induced reinforcement

Drug abuse and addiction are major problems in the United States. In particular methamphetamine (METH) use has increased dramatically. A greater understanding of how METH acts on the brain to induce addiction may lead to better therapeutic targets for this problem. The hippocampus is recognized as an important structure in learning and memory, but is not typically associated with drug reinforcement or reward processes. Here, the focus is on the hippocampus which has been largely ignored in the addiction literature as compared to the nucleus accumbens (NAc), ventral tegmental area (VTA), and prefrontal cortex (PFC). The results show that METH administered unilaterally via a microdialysis probe to rats’ right dorsal hippocampus will induce drug-seeking (place preference) and drug-taking (lever-pressing) behavior. Furthermore, both of these responses are dependent on local dopamine (DA) receptor activation, as they are impaired by a selective D₁/D₅ receptor antagonist. The results suggest that the hippocampus is part of the brain's reward circuit that underlies addiction.

Release of endogenous opioid peptides displaces [3H]diprenorphine binding in rat hippocampal slices

Pharmacological depolarization by KCl or veratrine reduced [3H]diprenorphine binding to opioid receptors in the hippocampal slice in a transient, calcium-dependent, and peptide-sensitive manner. These results suggest that endogenous opioid peptides were released from synaptic terminals and competitively displaced [3H]diprenorphine binding to opioid receptors. [3H]diprenorphine binding was significantly reduced by calcium-dependent depolarization throughout the hippocampus as determined by subsequent receptor autoradiography and quantitative densitometry. Displacement of binding was evident at sites in the CA1 and CA3 regions, the dentate gyrus, and the subiculum. The most dramatic reduction was evident in stratum lacunosum moleculare of CA3. Correlating the sites of maximal [3H]diprenorphine displacement with the previously described distribution of the opioid peptides suggests that the perforant path fibers release enkephalins in stratum lacunosum moleculare of CA3 and stratum moleculare of the dentate gyrus, and that mossy fibers may release both dynorphins and enkephalins near stratum pyramidale of CA3 and stratum granulosum. The lack of complete overlap between the distribution of opioid terminals and the sites of displacement indicates that these peptides may diffuse a moderate distance to their sites of action. Radioligand displacement defines the sites of endogenous opioid binding, suggests the likely sources of peptide release, and thus predicts the sites of endogenous opioid action within the hippocampus.

Synaptic pharmacology of the hippocampus

There is a wealth of information available regarding the complex synaptic pharmacology of the mammalian hippocampus. It is clear that many neurotransmitters are present in the hippocampus. Fig. 3 is an attempt to summarize in a schematic manner some of the synaptic connections of this structure and the neurotransmitters involved. The pyramidal cell and its inputs are shown and how various neurotransmitters modify its action in an excitatory (+) and inhibitory (-) manner. The hippocampus is an excellent model system for studying not only normal brain physiology, but also pathologic processes such as seizures, aging, etc. In view of the important role of the hippocampus in learning and memory and other brain functions, it is essential that the detailed synaptic mechanisms of the hippocampus be thoroughly understood. The present review is an attempt to integrate our knowledge of this structure into a rational basis for understanding how it functions and how it can be modified by pharmacological agents.